<DOC>
	<DOCNO>NCT00157573</DOCNO>
	<brief_summary>GM-CSF immunostimulant preliminary data suggests may change natural history prostate cancer melanoma . This study look ability GM-CSF alter disease progression woman recurrent asymptomatic recurrence ovarian cancer .</brief_summary>
	<brief_title>GM-CSF Women With Recurrent Ovary Cancer</brief_title>
	<detailed_description>This open label , single arm phase II study GM-CSF deliver daily without break population healthy fit woman evidence recurrent asymptomatic mullerian malignancy ( ovarian cancer , fallopian tube cancer , primary peritoneal cancer ) . The main goal determine time treatment termination due disease progression toxicity .</detailed_description>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<criteria>Patients must history histologic cytologic diagnosis primary ovarian , primary peritoneal tubal carcinoma . Patients must asymptomatic cancer . Patients must evidence recurrent carcinoma , determine : A rise CA125 serum level great 35 U/mL two successive rise value recent value least 3 time nadir value . Or evidence evaluable measurable disease xray CT scan . Patients may receive concurrent antineoplastic therapy . All hormonal therapy use treatment modality ( i.e . tamoxifen , arimidex , etc ) must stop prior treatment protocol . Age &gt; 18 year . ECOG performance status &lt; 2 Known severe hypersensitivity GMCSF Other coexist malignancy malignancy diagnose within last 5 year , exception basal cell carcinoma cervical cancer situ concurrent superficial stage IB endometrial carcinoma Concomitant use antineoplastic therapy Treatment nonFDA approve investigational drug within 30 day Day 1 trial treatment Any unresolved chronic toxicity great CTC grade 2 previous anticancer therapy ( except alopecia ) Serum creatinine level great CTC grade 2 ( Â£ 1.5 x ULN ) Pregnancy breast feeding ( woman childbearing potential ) Severe uncontrolled systemic disease ( e.g. , unstable uncompensated respiratory , cardiac , hepatic , renal disease ) judge investigator . Significant clinical disorder laboratory find make potentially unsafe subject participate trial judge investigator . Patients currently receive investigational antineoplastic agent , systemic chemotherapy radiation therapy treatment . Patients clinical and/or radiographic evidence current impend bowel obstruction . Performance status &lt; 1 Ability understand willingness sign write informed consent document .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Asymptomatic</keyword>
	<keyword>Clinical trial</keyword>
	<keyword>Phase II</keyword>
	<keyword>GM-CSF</keyword>
	<keyword>Immunotherapy</keyword>
</DOC>